September 2012, Volume 32, Issue 3, pp 176-181
Date: 01 Sep 2012
Serum Adenosine deaminase activity in type 2 Diabetes Mellitus patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The assessment of insulin resistance is advantageous since it detects those at risk for the development of diabetes mellitus at early stages and minimizes complications. Various methods like euglycemic hyperinsulinemic clamp technique, fasting serum insulin levels, HOMA and QUICKI have been used to determine insulin sensitivity but they have limitations. Adenosine deaminase (ADA) is an enzyme that has been suggested to be important for modulating the bioactivity of insulin. The aim of this study was to determine the activity of serum adenosine deaminase (ADA) in patients of type 2 diabetes mellitus and to evaluate the role of serum adenosine deaminase as a marker for insulin resistance. The study recruited 46 subjects of Type 2 diabetes mellitus and 40 healthy controls matched for age and sex between May 2010 and November 2010. Fasting serum glucose, insulin, adenosine deaminase activity were estimated. QUICKI and HOMA were calculated. Serum ADA was positively correlated with fasting serum glucose, insulin, HOMA and negatively correlated with QUICKI in the diabetic group. At 95 % CI and a cut off of 36.91U/L serum ADA activity in the diabetic group showed a sensitivity and specificity of 98 % and 90 % respectively. Serum ADA activity was increased with an increase in insulin resistance in the diabetic population. ADA may be used as a marker of insulin resistance and can be employed as an effective tool in screening for insulin resistance and diabetes mellitus.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32 Suppl 1:S62–7.CrossRef
The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26:S5–20.
Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2:231–7.CrossRef
Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:15–26.CrossRef
Van der Weyden MB, Kelly WN. Human adenosine deaminase: distribution and properties. J Biol Chem. 1976;251:5448–56.PubMed
Baghanha MF, Pego A, Lima MA, et al. Serum and pleural adenosine deaminase correlation with lymphocyte populations. Chest. 1990;87:605–10.CrossRef
Ungerer JP, Oosthuizen HM, Bissbort SH, Vermaak WJ. Serum adenosine deaminase: isoenzymes and diagnostic application. Clin Chem. 1992;38:1322–6.PubMed
Kurtul N, Pence S, Akarsu E, et al. Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Medica(Hradec Kralove). 2004;47:33–5.
Warrier A, Rao NY, et al. Evaluation of Adenosine Deaminase activity and lipid peroxidation levels in Diabetes Mellitus. IJCB. 1995;10:9–13.
Gupta A, Gupta V, Agrawal S, Natu SM, Agrawal CG, Negi MPS, Tiwari S. Association between circulating leptin and insulin resistance, the lipid profile, and metabolic risk factors in North Indian adult women. BioScience Trends. 2010;4:325–32.PubMed
Giusti G, Galanti B. Colorimetric method. Adenosine deaminase. In: Bergmeyer HU, editor. Methods of enzymatic Analysis. 3rd ed. Weinheim: Verlag chemie; 1984. p. 315–23.
Green A, Newsholme EA. Sensitivity of glucose uptake and lipolysis of white adipocytes of the rat to insulin and effects of some metabolites. Biochem J. 1979;180:365–70.PubMed
Pérez-Aguilar MC, Goncalves L, Ibarra A, Bonfante-Cabarcas R. Adenosine deaminase as costimulatory molecule and marker of cellular immunity. Investig Clin. 2010;51:561–71.
Lambeir AM, Durinx C, Scharpé S, De Meester I, Dipeptidyl-peptidase IV. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Sciences. 2003;40:209–94.
Samsel M, Dzierzbicka K. Therapeutic potential of adenosine analogues and conjugates. Pharmacol Rep Online. 2011;63:601–17.
Kaya S, Cetin ES, Aridogan BC, Arikan S, Demirci M. Adenosine deaminase activity in serum of patients with hepatitis—a useful tool in monitoring clinical status. J Microbiol Immunol Infect. 2007;40:288–92.PubMed
Kobayashi F, Ikeda T, Marumo F, Sato C. Adenosine deaminase isoenzymes in liver disease. Am J Gastroenterol. 1993;88:266–71.PubMed
- Serum Adenosine deaminase activity in type 2 Diabetes Mellitus patients
International Journal of Diabetes in Developing Countries
Volume 32, Issue 3 , pp 176-181
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Adenosine deaminase
- Insulin resistance
- Diabetes mellitus